A US-based KOL at a tertiary care center discusses the evolving treatment landscape in gastric cancer, with a focus on biomarker-driven treatment decision-making, the prioritization of zolbetuximab over PD-1 inhibitors in CLDN18.2-positive disease, and the anticipated impact of zanidatamab as a new 1L standard for HER2-positive patients. The challenges of optimal sequencing across multiple biomarkers, the limitations of late-line treatment options, and the implications of MATTERHORN for perioperative management were also explored.

This interview was conducted on April 10, 2026. 

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.